Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing.

Genome medicine·2026
Same author

Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer.

NPJ breast cancer·2025
Same author

Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: a phase 1 trial.

Nature medicine·2024
Same author

Inhibition of lysine acetyltransferase KAT6 in ER<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: a phase 1 trial.

Nature medicine·2024
Same author

Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.

JCO precision oncology·2024

Related Experiment Video

Updated: Jun 20, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Predicting anthracycline benefit: have we made any progress?

Erica Moretti1, Catherine Oakman, Angelo Di Leo

  • 1Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.

Current Opinion in Oncology
|August 29, 2009
PubMed
Summary

Predicting response to anthracycline chemotherapy in breast cancer remains challenging. Current biomarkers like HER-2 and topoisomerase IIalpha are not yet reliable for guiding treatment decisions.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Experiment Videos

Last Updated: Jun 20, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Biomarker Discovery

Background:

  • Adjuvant therapy benefits vary among breast cancer patients.
  • Predictive biomarkers are needed to identify individuals who will benefit from anthracycline-based chemotherapy.

Purpose of the Study:

  • To review the current search for predictive biomarkers for anthracycline response in breast cancer.
  • To focus on the potential roles of HER-2 and topoisomerase IIalpha as predictive markers.

Main Methods:

  • Review of existing literature and meta-analyses.
  • Evaluation of biomarker detection methods and study designs.
  • Analysis of breast cancer heterogeneity and its impact on treatment response.

Main Results:

  • Anthracycline benefit appears restricted to HER-2 amplified disease, but HER-2 status alone is insufficient.
  • Subgroups within HER-2 negative disease may benefit from anthracyclines.
  • The predictive role and optimal detection of topoisomerase IIalpha remain unclear.

Conclusions:

  • Currently, neither HER-2 nor topoisomerase IIalpha status reliably guides anthracycline prescription.
  • Breast cancer heterogeneity suggests prediction may require tumor profiles, not single markers.
  • Future trials incorporating heterogeneity are needed for personalized patient care.